Patent intelligence · US
US 7259278
Anti-S-phase tubulin ligands
Anti-S-phase tubulin ligands
Patent details — US 7259278
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 21, 2007
- Expiration
- Aug 16, 2027
- Applicant
- Cytoskeleton, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K45/06
Quick answer
US 7259278 (Anti-S-phase tubulin ligands) is held by Cytoskeleton, Inc.. Status: granted. Granted Aug 21, 2007. Expires Aug 16, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cytoskeleton, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K45/06
More from Cytoskeleton, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Frequently asked questions
What is US patent 7259278?
US 7259278 (Anti-S-phase tubulin ligands) is held by Cytoskeleton, Inc.. Status: granted. Granted Aug 21, 2007. Expires Aug 16, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7259278?
Cytoskeleton, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 7259278 expire?
Our index shows an expiration date of Aug 16, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.